{
    "clinical_study": {
        "@rank": "104431", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Evaluate the effects of cladribine (2-chlorodeoxyadenosine; 2-CdA) on biochemical,\n      radiologic, and histologic parameters in patients with early stage primary sclerosing\n      cholangitis."
        }, 
        "brief_title": "Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis", 
        "condition": "Cholangitis, Sclerosing", 
        "condition_browse": {
            "mesh_term": [
                "Cholangitis", 
                "Cholangitis, Sclerosing"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      Patients are treated with subcutaneous injections of cladribine (2-chlorodeoxyadenosine;\n      2-CdA) for 5 consecutive days every month for 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Stage I-III primary sclerosing cholangitis\n\n        Radiologically and pathologically documented\n\n        No concomitant liver disease, e.g.:\n\n          -  Viral hepatitis\n\n          -  Autoimmune hepatitis\n\n          -  Primary biliary cirrhosis\n\n          -  Cirrhosis\n\n          -  Portal hypertension or associated complications\n\n          -  Jaundice caused by dominant stricture\n\n        --Prior/Concurrent Therapy--\n\n        No concurrent immunosuppressives\n\n        --Patient Characteristics--\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 2500/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n          -  Hemoglobin at least 10 g/dL\n\n        Other:\n\n          -  No active infection\n\n          -  No fistula abscess\n\n          -  No active inflammatory bowel disease\n\n          -  Quiescent disease allowed, including: Chronic ulcerative colitis Crohn's disease\n\n          -  No other significant immunologic disorder\n\n          -  No active malignancy\n\n          -  No active alcohol or drug abuse\n\n          -  No pregnant or nursing women\n\n          -  Effective contraception required of fertile patients\n\n        Endoscopic retrograde cholangiopancreatography within 36 months prior to registration\n\n        Liver biopsy within 12 months prior to registration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "5", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004762", 
            "org_study_id": "199/11707", 
            "secondary_id": "SCRF-94304"
        }, 
        "intervention": {
            "intervention_name": "cladribine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cladribine"
        }, 
        "keyword": [
            "gastrointestinal disorders", 
            "primary sclerosing cholangitis", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Scripps Clinic", 
            "last_name": "Paul J. Pockros", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004762"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Scripps Clinic", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 1994", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2001"
    }, 
    "geocoordinates": {}
}